全球制药巨头诺华和礼来近日宣布与Alphabet旗下AI制药企业Isomorphic Labs达成价值30亿美元的合作。这次战略合作重点关注小分子领域，通过运用人工智能技术，以期开发出更具创新性和疗效的药物。
根据合作协议，双方将共同开展多靶点研究，以加速药物研发进程。此次合作不仅为Isomorphic Labs带来了巨大的经济价值，还进一步巩固了其在AI制药领域的领导地位。
作为全球领先的制药公司，诺华和礼来在药物研发方面具有丰富经验。与Isomorphic Labs的合作将充分利用人工智能技术，提高药物研发的效率和成功率。此外，此次合作还有助于推动我国AI制药产业的发展，为患者带来更多创新药物。
英文翻译：
News title: Novartis, Lilly and Alphabet’s AI Pharmaceutical Company Ink $3 Billion Deal
Keywords: AI pharmaceuticals, strategic cooperation, small molecules
News content:
Global pharmaceutical giants Novartis and Lilly have recently announced a $3 billion cooperation deal with Alphabet’s AI pharmaceutical company, Isomorphic Labs. This strategic partnership focuses on the field of small molecules, aiming to develop more innovative and effective drugs through the use of artificial intelligence technology.
Under the cooperation agreement, the two parties will jointly carry out multi-target research to accelerate the drug development process. This cooperation not only brings significant economic value to Isomorphic Labs but also further consolidates its leadership in the AI pharmaceutical field.
As leading global pharmaceutical companies, Novartis and Lilly have extensive experience in drug development. The cooperation with Isomorphic Labs will fully leverage artificial intelligence technology to improve the efficiency and success rate of drug development. Furthermore, this collaboration promotes the development of AI pharmaceutical industry in China and brings more innovative drugs to patients.
【来源】https://news.cnstock.com/industry,rdjj-202401-5173731.htm
Views: 1